Br J Cancer. 1993 Jul;68(1):146-50. doi: 10.1038/bjc.1993.303.
Six hundred and eighty-four primary breast cancers from the International (Ludwig) Breast Cancer Study Group (IBCSG) were studied for Helix pomatia lectin (HPA) binding. There was a weak correlation between lymph node-positive and HPA positive (P = 0.04). In our series there was a large advantage in disease-free survival (DFS) and overall survival (OS) for node-negative patients (P < 0.0001 DFS and OS). However, there was no such advantage for HPA-negative patients (P = 0.23 DFS and P = 0.32 OS). We conclude that in this randomised patient group HPA is of no clinical predictive value.
对来自国际（路德维希）乳腺癌研究组（IBCSG）的684例原发性乳腺癌进行了关于蜗牛凝集素（HPA）结合的研究。淋巴结阳性与HPA阳性之间存在弱相关性（P = 0.04）。在我们的系列研究中，淋巴结阴性患者的无病生存期（DFS）和总生存期（OS）有很大优势（DFS和OS，P < 0.0001）。然而，HPA阴性患者没有这样的优势（DFS，P = 0.23；OS，P = 0.32）。我们得出结论，在这个随机分组的患者群体中，HPA没有临床预测价值。
